Q32 Bio filed a prospectus for an offer and resale of 6.875 million shares by selling stockholders. The filing outlines the terms of the proposed transaction.

The prospectus provides details regarding the shares to be sold by the stockholders. This filing is a regulatory requirement for the offer and resale process.

Q32 Bio Inc. (NASDAQ: QTTB) stock traded lower after the company priced a public offering expected to raise approximately $200 million in gross proceeds. The offering consists of 6,027,399 shares of common stock at a public offering price of $18.25 per share and pre-funded warrants to purchase 4,931,506 shares at a public offering price of $18.2499 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.0001 per share. The offering is expected to close on or about July 16, 2026, subject to customary closing conditions.

Q32 Bio intends to use the net proceeds for working capital purposes, covering expenses related to research, clinical development, and commercialization efforts. The funds will specifically support the advancement of bempikibart, a fully human anti-IL-7Rα antibody undergoing evaluation in an ongoing Phase 2 program for alopecia areata. The company has granted the underwriters a 30-day option to purchase up to an additional 1,643,835 shares of common stock at the public offering price, less underwriting discounts and commissions.

Underwriting Details

Morgan Stanley, Jefferies, and Cantor are acting as joint book-running managers for the offering. Oppenheimer & Co. is also acting as a book-running manager, while H.C. Wainwright & Co. is acting as lead manager for the offering.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-297027) filed with the Securities and Exchange Commission (SEC) on June 25, 2026, and declared effective on July 13, 2026.

Market Reaction and Outlook

Analysts expect Q32 Bio to report earnings on Aug. 5, 2026, with a projected loss of 56 cents per share on revenue of $600,000. The stock carries a Strong Buy consensus rating and an average price forecast of $33.25. Wells Fargo upgraded the stock to Overweight with a $66 price target on July 13, while Oppenheimer maintained an Outperform rating and raised its target to $40. Q32 Bio shares were down 7.42% at $18.25 at the time of publication.